Comparative Pharmacology
Head-to-head clinical analysis: LENVIMA versus OFEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENVIMA versus OFEV.
LENVIMA vs OFEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lenvatinib is a multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. It inhibits angiogenesis, tumor growth, and progression by blocking these receptor tyrosine kinases.
Nintedanib is a tyrosine kinase inhibitor that blocks the activity of fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), thereby inhibiting fibroblast proliferation, migration, and transformation, and reducing extracellular matrix deposition.
24 mg orally once daily for differentiated thyroid carcinoma; 18 mg orally once daily plus everolimus 5 mg orally once daily for renal cell carcinoma; 12 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks for endometrial carcinoma; 8 mg orally once daily (or 10 mg for patients with body weight ≥60 kg) plus pembrolizumab 200 mg intravenously every 3 weeks for hepatocellular carcinoma.
150 mg orally twice daily, taken with food.
None Documented
None Documented
Terminal elimination half-life is approximately 28 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 38 hours (range 30–48 hours) at steady state, supporting once-daily dosing.
Approximately 71% of the dose is excreted in feces (34% as unchanged drug) and 25% in urine (0.4% as unchanged).
Primarily biliary/fecal (~93.4% of total radioactivity recovered in feces), renal excretion is minor (~0.6% unchanged in urine).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor